(Q33417304)

English

Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michelle Sholzberg

object named as

Michelle Sholzberg

2

0 references

author name string

Anca Prica

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rena Buckstein

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

26 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

167

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

626-638

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Platelet function and its clinical significance in the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13088

21 January 2018

Identifiers

10.1111/BJH.13088

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33417304&oldid=1644978189"